A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder

Running, not enrolling · Phase 2 · Has a placebo group

Conditions studied: Major Depressive Disorder

In brief

This is a Phase 2B clinical study evaluating the effectiveness and safety of SP-624 as compared to placebo in the treatment of adults with Major Depressive Disorder.

Key facts

Study ID
NCT06254612
Run by
Sirtsei Pharmaceuticals, Inc.
People needed
456
Starts
2024-03-25
Expected to finish
2026-07-15
Last updated by the study team
2026-05-15

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.